|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
HPO |
|
|
|
|
Malignant neoplasm of stomach
|
0.700 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Malignant neoplasm of stomach
|
0.700 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
This antibody detected K-sam proteins by Western blot and flow cytometry analyses in stomach cancer cell lines KATO-III and HSC39, in which the K-sam gene is amplified and overexpressed.
|
9816310 |
1996 |
|
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
FGFR2 gene is preferentially amplified and overexpressed in diffuse-type gastric cancer.
|
16773196 |
2006 |
|
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
KGFR expression tended to correlate with a good prognosis in gastric cancer.
|
16391783 |
2006 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
In addition, several FGFRs are mutated in human cancers (including FGFR2 in gastric cancer and FGFR3 in bladder cancer).
|
17697126 |
2007 |
|
Malignant neoplasm of stomach
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
Thus, our results suggest that the epigenetic silencing of FGFR2 through DNA methylation in gastric cancer may contribute to tumor progression.
|
17459342 |
2007 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Inhibitors of FGFR2 or Erbb3 signaling may have therapeutic efficacy in the subset of gastric cancers containing FGFR2 amplification.
|
18381441 |
2008 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Amplifications of certain RTKs (c-Met, FGFR2 and ErbB2) have been associated with human gastric cancer progression.
|
20331976 |
2010 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
CTD_human |
Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.
|
21936542 |
2011 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
FGFR2 amplification was observed in 4.1% of gastric cancers and our established PCR-based copy number assay could be a powerful tool for detecting FGFR2 amplification using FFPE samples.
|
22240789 |
2012 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
CTD_human |
Thus, combined expression of MYC, EGFR and FGFR2 is predictive of poor survival in CF-treated metastatic gastric cancer patients.
|
21173787 |
2012 |
|
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Clinical significance of keratinocyte growth factor and K-sam gene expression in gastric cancer.
|
23545898 |
2013 |
|
Malignant neoplasm of stomach
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Amplification of the FGFR2 gene was identified in a subset of Chinese and Caucasian patients with gastric cancer.
|
23493349 |
2013 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
A similar incidence of FGFR2 amplification was found in Asian and UK GCs and was associated with lymphatic invasion and poor prognosis.
|
24457912 |
2014 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Applying dual-colour FISH on 137 gastric tumours (89 FFPE surgical resections and 48 diagnostic biopsies), we observed FGFR2 amplification in 7.3% and HER2 amplification in 2.2% of GCs.
|
25086186 |
2014 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Deep-sequencing of a primary tumor and metastasis from a single patient, and functional validation in culture, reveals that TGFBR2 and FGFR2 act as drivers of gastric cancer.
|
25222187 |
2014 |
|
Malignant neoplasm of stomach
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The correlations between anti-tumour sensitivity and the molecular segments of HER2, MET and FGFR2 alterations were further tested in a panel of GC cell lines and the patient-derived GC xenograft (PDGCX) model using the targeted inhibitors.
|
24518603 |
2014 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
FGFR2 is amplified in breast and gastric cancer, and we report here the first characterization of FGFR2 gene amplification in colorectal cancer in the NCI-H716 colorectal cancer cell line.
|
24968263 |
2014 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Copy number gain of MIR17HG gene (13q31.3) was rare, with an overall frequency of 2% in gastric cancers (1 of 51). miR-17 knockdown suppressed the monolayer and anchorage-independent growth of FGFR2-amplified KATO-III gastric cancer cells. mir-17-92 TG/TG mice overexpressing the mir-17-92 cluster under the villin promoter developed spontaneous benign tumors in the intestinal tract (log-rank P for tumor-free survival = 0.069).
|
25047501 |
2014 |
|
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Evaluation of Fibroblast Growth Factor Receptor 2 Expression, Heterogeneity and Clinical Significance in Gastric Cancer.
|
26516773 |
2015 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
It will be clinically valuable to investigate the involvement of RTK-mediated signaling in intrinsicor acquired resistance to FGFR2 TKIs in GC.
|
25576915 |
2015 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
FGFR2 Assessment in Gastric Cancer Using Quantitative Real-Time Polymerase Chain Reaction, Fluorescent In Situ Hybridization, and Immunohistochemistry.
|
25972329 |
2015 |
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Amplification of FGFR2 Gene in Patients with Advanced Gastric Cancer Receiving Chemotherapy: Prevalence and Prognostic Significance.
|
26254407 |
2015 |